Key Insights on Gross Profit: Catalent, Inc. vs Ascendis Pharma A/S

Catalent vs Ascendis: A Decade of Gross Profit Dynamics

__timestampAscendis Pharma A/SCatalent, Inc.
Wednesday, January 1, 201413983000598600000
Thursday, January 1, 20158118000615300000
Friday, January 1, 20164606000587600000
Sunday, January 1, 20171530000654600000
Monday, January 1, 201810581000752600000
Tuesday, January 1, 201913375000805100000
Wednesday, January 1, 20206953000983300000
Friday, January 1, 202142550001352000000
Saturday, January 1, 2022390370001640000000
Sunday, January 1, 20232223230001060000000
Monday, January 1, 2024319383000953000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: Catalent, Inc. vs Ascendis Pharma A/S

In the dynamic world of pharmaceuticals, Catalent, Inc. and Ascendis Pharma A/S have showcased contrasting trajectories in gross profit over the past decade. Catalent, Inc., a leader in drug development, consistently demonstrated robust growth, peaking in 2022 with a gross profit increase of approximately 175% since 2014. In contrast, Ascendis Pharma A/S, a biopharmaceutical innovator, experienced a dramatic surge in 2023, with gross profits skyrocketing by over 1500% compared to 2014. This remarkable growth highlights Ascendis Pharma's strategic advancements and market penetration. However, the data for 2024 remains incomplete, leaving room for speculation on future trends. As the pharmaceutical landscape evolves, these companies exemplify the diverse paths to success, driven by innovation and market demand.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025